title: (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation.
abstract: Osteosarcoma is one of the most common pediatric cancers. Accurate imaging of osteosarcoma is important for proper clinical staging of the disease and monitoring of the tumor's response to therapy. The MYC oncogene has been commonly implicated in the pathogenesis of human osteosarcoma. Previously, we have described a conditional transgenic mouse model of MYC-induced osteosarcoma. These tumors are highly invasive and are frequently associated with pulmonary metastases. In our model, upon MYC inactivation osteosarcomas lose their neoplastic properties, undergo proliferative arrest and differentiate into mature bone. We reasoned that we could use our model system to develop noninvasive imaging modalities to interrogate the consequences of MYC inactivation on tumor cell biology in situ. We performed positron emission tomography (PET) combining the use of both (18)F-fluorodeoxyglucose ((18)FDG) and (18)F-flouride ((18)F) to detect metabolic activity and bone mineralization/remodeling. We found that upon MYC inactivation, tumors exhibited a slight reduction in uptake of (18)FDG and a significant increase in the uptake of (18)F along with associated histological changes. Thus, these cells have apparently lost their neoplastic properties based upon both examination of their histology and biologic activity. However, these tumors continue to accumulate (18)FDG at levels significantly elevated compared to normal bone. Therefore, PET can be used to distinguish normal bone cells from tumors that have undergone differentiation upon oncogene inactivation. In addition, we found that (18)F is a highly sensitive tracer for detection of pulmonary metastasis. Collectively, we conclude that combined modality PET/CT imaging incorporating both (18)FDG and (18)F is a highly sensitive means to non-invasively measure osteosarcoma growth and the therapeutic response, as well as to detect tumor cells that have undergone differentiation upon oncogene inactivation.
authors.affiliation: Department of Chemical and Systems Biology, Stanford School of Medicine, Stanford, California 94403, USA.
authors.forename: Constadina
authors.initials: C
authors.lastname: Arvanitis
authors.forename: Pavan K
authors.initials: PK
authors.lastname: Bendapudi
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Tseng
authors.forename: Sanjiv Sam
authors.initials: SS
authors.lastname: Gambhir
authors.forename: Dean W
authors.initials: DW
authors.lastname: Felsher
mesh_terms: D000818:Animals; D001846:Bone Development / Q000528:radiation effects; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000235:genetics / Q000473:pathology*; D001842:Bone and Bones / Q000473:pathology*; D002454:Cell Differentiation; D002455:Cell Division; D004195:Disease Models, Animal; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D020868:Gene Silencing; D016259:Genes, myc; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009361:Neoplasm Invasiveness; D012516:Osteosarcoma / Q000000981:diagnostic imaging* / Q000235:genetics / Q000473:pathology*; D049268:Positron-Emission Tomography; D011859:Radiography
chemical_list: D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18